Statistics from Altmetric.com
Nash P, Behrens F, Orbai A, et al. Ixekizumab is efficacious when used alone or when added to conventional synthetic disease-modifying antirheumatic drugs (cDMARDs) in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor inhibitors. RMD Open 2018;4:e000692. doi: 10.1136/rmdopen-2018-000692
This article has been corrected since it first published. There were some copyediting errors which have been rectified now.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.